MedTrace Logo

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

NCT01078636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 342

Last updated 2014-09-16

No results posted yet for this study

Summary

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Conditions

Sponsors & Collaborators

  • Northern California Institute of Research and Education

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Alzheimer's Disease Cooperative Study (ADCS)

    lead OTHER

Principal Investigators

  • Ronald Petersen, MD, PhD · Mayo Clinic - Rochester, Minnesota

  • Michael W Weiner, MD · University of California, San Francisco

  • Paul Aisen, MD · University of California, San Diego

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078636 on ClinicalTrials.gov